June 15, 2016 at 7:00 pm #92389iowagirlMember
Thank you everyone for your participation and representation for all of us.June 15, 2016 at 5:17 pm #92388karendParticipant
-KarenJune 15, 2016 at 5:12 pm #92387
Yay!!!!! Thanks for that Melinda! What a great pic of you all at the booth, love it!!!
And of course, my thanks to you all who were there!
Hugs and thanks!
GavinJune 14, 2016 at 10:36 pm #92386mbachiniModeratorJune 9, 2016 at 8:35 pm #92385lainyParticipant
Thank you to our wonderful team who are always representing all of us and our cause. We and this Foundation are all so blessed to have you. Again, thank you for all you do!June 9, 2016 at 8:30 pm #92384jacdollMember
Thank you both – Gavin and Marion!
We are positive and hopeful but don’t want to get our hopes up too much. His counts aren’t necessarily high enough to restart the trial but if by some miracle they are tomorrow then Tom will restart and I think we will both release a deep sigh of relief. The last week has been so stressful. We are ready for some good news!
We really appreciate all the support – as always! This is such a fantastic community of friends with so much knowledge amongst us, I love it!
Eager to hear how things are going for Kris too, so follow-up when you can! My fingers are crossed that this drug works for you too. It’s a lot of taking the pills and waiting, I know. Makes you feel like you don’t have much of an update!
Take care everyone and I will update this weekend.
AshJune 9, 2016 at 5:38 pm #92383
Ash and Tom……thank you, so happy to hear of Tom’s excellent recovery. Know that the entire cholangiocarcinoma community is behind you and Tom and that a tidal wave of good wishes are heading your way.
MarionJune 9, 2016 at 5:31 pm #92382
Thanks Marion, glad to help as always! Hope that ASCO was good and that you are putting your feet up for a well earned rest! Yet again pretty much all I heard on CNBC re ASCO was about immonotherapy and that really seems to be making huge advances all round with trials etc. Bring it on!!
Hope that all goes well In Atlanta for Tom Ash and please let us know how it goes. Fingers crossed for you!
Hugs to all,
GavinJune 8, 2016 at 2:40 am #92381
Gavin….you are fantastic. Thank you for posting the abstracts for us all.
MarionJune 7, 2016 at 11:23 pm #92380
Vice President Joe Biden Discusses Cancer Moonshot Initiative During ASCO 2016
You may watch the video with this link:
MarionJune 5, 2016 at 7:52 pm #92378
Thanks for this Marion, great news! And my thanks to all the team as well!
Am away to post the abstracts from this years meeting, lots of papers, 36 of them!
Hugs to all of you,
GavinJune 5, 2016 at 2:01 am #92379debnorcalModerator
A huge thank you to all of you for attending this conference and reporting the latest information to our group. Your generosity is so very much appreciated!
DebbieJune 4, 2016 at 7:59 pm #12475
“Collective Wisdom” is the theme for this year’s ASCO.
Our attending team includes Melinda, Barbara, Jason, Andie, Kathi, Donna, Stacie and myself. Melinda and Barbara are staffing the exhibit while the rest of us are dispersed throughout the conference halls attending sessions or connecting with the various biopharma industry, researchers, physicians and advocates. It’s wonderful to meet up with Lisa, a long time CCA survivor, so well known to us.
In the past 5 years, cancer immunotherapy has captured the attention of the medical community and the general public; however scientists are questioning the challenges of successfully integrating immune-oncology in cancer care. We know that immunotherapy research is still in its infancy. Many scientists and doctors around the world are studying new ways to use immunotherapy to treat cancer.
There is not a clear understanding as to why some patients respond to immunotherapy whereas other do not. PD-1 inhibitors, such as pembrolizumab (Keytruda), nivolumab (Opdivoa) and adoptive T-Cell therapy have shown excellent results in a subset of our patients, but other patients have not had similar results.
Researchers are trying to gain a better understanding of the intended immune reaction and how it is related to genetic changes driving the ability of a tumor to induce an immune response.
They also are trying to identify targeted cancer drugs that hat block the growth and spread of cancer by interfering with specific molecules (“molecular targets”) that are involved in the growth, progression, and spread of cancer.
There was talk of combination therapies i.e. including other drugs (biologic, non-biologic or chemotherapy agents) leading to better patient response. Discussions centered around multiple types of immunotherapy combinations and potential combinations such as checkpoint plus adoptive T-cell transfer (Melinda’s NIH trial) with T-cell engineering, checkpoint and and small molecules such as VEGF, EGFR, or BRAF, checkpoint and cancer vaccine, checkpoint and chemotherapy and combination of checkpoint inhibitors such as Keytruda and Opdivo with added radiation.
Note: What is a checkpoint inhibitor?
An important part of the immune system is its ability to tell between normal cells in the body and those it sees as “foreign.” This lets the immune system attack the foreign cells while leaving the normal cells alone. To do this, it uses “checkpoints” – molecules on certain immune cells – that need to be activated (or inactivated) to start an immune response.
In order to gain a better understanding of the science and possible benefits of enrolling in these type of clinical research studies, hundreds of clinical trials are currently conducted and many more are yet to follow.
As these clinical research studies are brought to our attention, the Cholangiocarcinoma Foundation will continue to update you on all developments.
- You must be logged in to reply to this topic.